Latest Breaking News On - Genetical recombination - Page 1 : comparemela.com

For Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma Tokyo, May 19, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has launched the anticancer agent Remitoro® for Intravenous Drip Infusion 300µg (Denileukin Diftitox (Genetical Recombination)) with the indications of relapsed or refractory Peripheral T-cell Lymphoma (PTCL) and relapsed or refractory Cutaneous T-cell Lymphoma (CTCL), in Japan. Eisai obtained the manufacturing and marketing approval of Remitoro on March 23, 2021. Remitoro was included to Japan s National Health Insurance Drug Price List on May 19, 2021. The agent is a fusion protein consisting of interleukin-2 (IL-2) and partial sequence of diphtheria toxin, and specifically binds to the IL-2 receptor on the surface of tumoral lymphocytes. The antitumor efficacy of denileukin diftitox is believed to depend on the intracellular delivery of diphtheria toxin fragment which inhibits protein synthesis and induce cell death.

Kostenloser wertpapierhandelEisai co ltdMinistry of healthStudy group for unapproved drugs offPeripheralt cell lymphomaCutaneoust cellIntravenous drip infusionDenileukin diftitoxGenetical recombinationCutaneoust cell lymphomaNational health insurance drug price listOff label drugsHigh medicalAnti cancerேசை இணை லிமிடெட்அமைச்சகம் ஆஃப் ஆரோக்கியம்